Details for New Drug Application (NDA): 204038
✉ Email this page to a colleague
NDA 204038 describes VALSARTAN, which is a drug marketed by Novitium Pharma, Alembic, Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Dr Reddys, Hetero Labs Ltd V, Ivax Pharms, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, Mylan, Ohm Labs Inc, Prinston Inc, Ryan Labs, Sciegen Pharms Inc, Square Pharms, Torrent, Unichem, Watson Labs Inc, Zydus Lifesciences, Apotex Inc, Mylan Pharms Inc, and Watson Labs Teva, and is included in thirty-one NDAs. It is available from thirty-four suppliers. Additional details are available on the VALSARTAN profile page.
The generic ingredient in VALSARTAN is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.
The generic ingredient in VALSARTAN is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.
Summary for 204038
| Tradename: | VALSARTAN |
| Applicant: | Sciegen Pharms Inc |
| Ingredient: | valsartan |
| Patents: | 0 |
Pharmacology for NDA: 204038
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for 204038
Suppliers and Packaging for NDA: 204038
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VALSARTAN | valsartan | TABLET;ORAL | 204038 | ANDA | ScieGen Pharmaceuticals, INC. | 50228-132 | 50228-132-05 | 500 TABLET in 1 BOTTLE (50228-132-05) |
| VALSARTAN | valsartan | TABLET;ORAL | 204038 | ANDA | ScieGen Pharmaceuticals, INC. | 50228-132 | 50228-132-30 | 30 TABLET in 1 BOTTLE (50228-132-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 40MG | ||||
| Approval Date: | Oct 27, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 80MG | ||||
| Approval Date: | Oct 27, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 160MG | ||||
| Approval Date: | Oct 27, 2021 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
